|
Collaboration Arrangements - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
12 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2013
Merck KGaA [Member]
|
Dec. 31, 2012
Merck KGaA [Member]
|
Dec. 31, 2013
Merck KGaA [Member]
Subsequent Event [Member]
|
Dec. 31, 2013
Merck KGaA [Member]
Regulatory and Development Milestones [Member]
|
Dec. 31, 2013
Merck KGaA [Member]
Commercialization Milestones [Member]
|
Dec. 31, 2013
Eleison Pharmaceuticals, Inc. [Member]
|
Dec. 31, 2011
Eleison Pharmaceuticals, Inc. [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||
| Upfront and milestone payments received to date | $ 110.0 | $ 12.5 | |||||||
| Potential future milestones | 100 | 340 | |||||||
| Merck KGaA's percentage share of worldwide development expenses | 70.00% | ||||||||
| Portion of profits that Company is eligible to participate in United States, depending upon total sales | 50.00% | ||||||||
| Revenue recognized by the Company | 12.5 | 5.9 | |||||||
| Collaboration payments achieved and received | 42.5 | 67.5 | |||||||
| Company earned a reimbursement for eligible worldwide development expenses | 16.5 | 13.1 | |||||||
| Percentage of profits from commercialization | 50.00% | ||||||||
| Revenue recognized by the Company | $ 0 | $ 0 | $ 0.1 | ||||||
| X | ||||||||||
|
- Definition
Collaboration payments achieved and received. No definition available.
|
| X | ||||||||||
|
- Definition
Collaboration Upfront and Milestone Payments received and/or earned. No definition available.
|
| X | ||||||||||
|
- Definition
Percentage Of Profits From Commercialization No definition available.
|
| X | ||||||||||
|
- Definition
Portion of profits in united states depending on total sales. No definition available.
|
| X | ||||||||||
|
- Definition
Potential milestone payments. No definition available.
|
| X | ||||||||||
|
- Definition
Reimbursement expenses. No definition available.
|
| X | ||||||||||
|
- Definition
Worldwide development expenses share percentage. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|